文献速递认知障碍与痴呆

阿尔茨海默病中tau蛋白、β淀粉样蛋白与皮层厚度同认知的关联

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
PubMed 文献 · Neurology · 2019-01-09

本研究基于BioFINDER队列106名受试者,分析tau PET、Aβ PET及皮层厚度与认知的横断面关联。结果显示临床前AD阶段仅tau PET与认知下降相关,临床阶段tau PET和皮层厚度与多项认知测试强相关,Aβ PET关联较弱。

要点

  • 临床前AD中tau PET与整体认知、记忆及处理速度下降相关。
  • 临床AD阶段tau PET和皮层厚度与多项认知测试表现相关。
  • Aβ PET对认知的关联较弱且区域特异性低。

核心结论

  • tau PET比Aβ PET和皮层厚度更敏感地检测临床前AD的早期认知变化。
  • 在AD临床阶段,tau PET和皮层厚度均与认知强烈相关。

研究设计与样本

  • 横断面研究纳入瑞典BioFINDER队列106名参与者,其中临床前AD 33例、前驱期AD 25例、很可能AD痴呆48例。
  • 所有参与者接受[18F]flortaucipir tau PET和 structural MRI,其中88例接受[18F]flutemetamol Aβ PET。
  • 采用线性回归模型(校正年龄、性别和教育)分析7个感兴趣区与7项神经心理测试的关联。

主要发现

  • 临床前AD中,[18F]flortaucipir与整体认知、记忆和处理速度下降相关(标准化β=0.35-0.52,p<0.05未校正多重比较)。
  • 前驱期AD和AD痴呆合并组中,[18F]flortaucipir摄取增加和皮层厚度减少与多项神经心理测试表现差相关(多数感兴趣区经多重比较校正后p<0.05)。
  • 合并组中[18F]flutemetamol摄取增加仅与延迟回忆记忆任务得分低相关(p<0.05未校正多重比较)。
  • tau PET和皮层厚度对认知的最强效应位于外侧和内侧顶叶皮层及外侧颞叶皮层。
  • Aβ PET对认知的效应总体较弱且区域特异性较低。

临床怎么用

  • 在临床前AD阶段,tau PET可能比Aβ PET和皮层厚度更能提示早期认知改变。
  • 在AD临床阶段,tau PET和皮层厚度可作为认知损害的影像学关联指标。

局限性

  • 部分关联未校正多重比较,可能增加假阳性风险。
  • Aβ PET仅88例完成,样本量较小。
  • 横断面设计无法推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cortical thickness and neuropsychological function across the preclinical and clinical spectrum of Alzheimer disease (AD). METHODS: We included 106 participants from the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study, of whom 33 had preclinical AD (Aβ-positive cognitively normal individuals), 25 had prodromal AD (Aβ-positive mild cognitive impairment), and 48 had probable AD dementia. All underwent [18F]flortaucipir (tau) and structural MRI (cortical thickness), and 88 of 106 underwent [18F]flutemetamol (Aβ) PET. Linear regression models adjusted for age, sex, and education were performed to examine associations between 7 regions of interest and 7 neuropsychological tests for all 3 imaging modalities. RESULTS: In preclinical AD, [18F]flortaucipir, but not [18F]flutemetamol or cortical thickness, was associated with decreased global cognition, memory, and processing speed (range standardized β = 0.35-0.52, p < 0.05 uncorrected for multiple comparisons). In the combined prodromal AD and AD dementia group, both increased [18F]flortaucipir uptake and reduced cortical thickness were associated with worse performance on a variety of neuropsychological tests (most regions of interest survived correction for multiple comparisons at p < 0.05), while increased [18F]flutemetamol uptake was specifically associated with lower scores on a delayed recall memory task (p < 0.05 uncorrected for multiple comparisons). The strongest effects for both [18F]flortaucipir and cortical thickness on cognition were found in the lateral and medial parietal cortex and lateral temporal cortex. The effect of [18F]flutemetamol on cognition was generally weaker and less region specific. CONCLUSION: Our findings suggest that tau PET is more sensitive than Aβ PET and measures of cortical thickness for detecting early cognitive changes in preclinical AD. Furthermore, both [18F]flortaucipir PET and cortical thickness show strong cognitive correlates at the clinical stages of AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019. PMID: 30626656. doi:10.1212/WNL.0000000000006875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。